We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Microglia Stem Cell Protocol Optimized For High-Throughput Experiments
News

Microglia Generation For High-Throughput Experiments Optimized

New Microglia Stem Cell Protocol Optimized For High-Throughput Experiments
News

Microglia Generation For High-Throughput Experiments Optimized

Microglia derived from stem cells. Credit: NYSCF
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "New Microglia Stem Cell Protocol Optimized For High-Throughput Experiments"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Scientists from the New York Stem Cell Foundation (NYSCF) Research Institute have developed a robust, efficient method for deriving microglia, the immune cells of the brain, from human stem cells. Microglia are increasingly implicated in neurological disorders including Alzheimer’s disease, Parkinson’s disease and multiple sclerosis, among many others. However, research into the role of human microglia in these disorders has long been hampered by the inability to obtain them from the human nervous system. 


This new protocol now enables scientists around the world to generate this critical cell type from individual patients and improve our understanding of the role of microglia neurological malfunction. “NYSCF’s mission is to bring cures to patients faster,” said Susan L. Solomon, CEO and cofounder of NYSCF. “One way we work towards this goal is by developing methods and models that lift the entire field of stem cell research. This new protocol is the perfect example of the type of method that will enable researchers around the world to accelerate their work.” 


Published in Stem Cell Reports, this microglia protocol is optimized for use in high-throughput experiments, such as drug screening and toxicity testing among other large-scale research applications, and has the benefit of allowing such experiments to be carried out on multiple patient samples. The scientists determined that the protocol is robust and reproducible, generating microglia from sixteen induced pluripotent stem (iPS) cell lines, stem cells that are created from individual patients.


Microglia from humans have long been a desired research model, but are difficult to obtain for laboratory experiments. The NYSCF protocol provides a new source of human microglia cells, which can be generated from disease patient samples and will complement studies in mouse models to better understand the role of microglia in health and disease. Microglia generated by the NYSCF protocol will thus provide a critical tool to investigate microglia dysfunction in central nervous system disorders and advance complex disease modeling in a dish. 

This article has been republished from materials provided by NYSCF. Note: material may have been edited for length and content. For further information, please contact the cited source.


Advertisement